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Dietary N-Glycans from Bovine Lactoferrin and TLR
Modulation
Susana Figueroa-Lozano,* Rivca L. Valk-Weeber, Sander S. van Leeuwen,
Lubbert Dijkhuizen, and Paul de Vos
Scope: Bovine lactoferrin (bLF) is an ingredient of food supplements and
infant formulas given its antimicrobial and antiviral properties. We modiﬁed
bLF enzymatically to alter its N-glycosylation and to isolate the glycan chains.
The aims of this study include (1) to evaluate whether such derivates induce
responses via pattern recognition receptors namely Toll-like receptors (TLRs)
and (2) to relate those responses to their diﬀerent glycosylation proﬁles.
Methods and results: The unmodiﬁed and modiﬁed bLF fractions are
incubated with reporter cell lines expressing pattern recognition receptors.
Afterwards, we screen for TLRs and analyze for nuclear factor
kappa—light-chain enhancer of activated B cells (NF-κB) activation.
Activation of reporter cell lines show that signaling is highly dependent on
TLRs. The activation pattern of bLF is reduced with the desialylated form and
increased with the demannosylated form. In reporter cells for TLR, bLF
activate TLR-4 and inhibit TLR-3. The isolated glycans from bLF inhibit TLR-8.
TLR-2, TLR-5, TLR-7, and TLR-9 are not signiﬁcantly altered.
Conclusion: The proﬁle of glycosylation is key for the biological activity of
bLF. By understanding how this aﬀects the human defense responses, the
bLF glycan proﬁle can be modiﬁed to enhance its immunomodulatory eﬀects
when used as a dietary ingredient.
1. Introduction
Milk substitutes and infant formulas play an important role in
infant nutrition when breastfeeding is not possible.[1] Among
all the human milk components, lactoferrin (LF) is considered
one of the most important elements for the newborns defense
against infections and proper development and maturation of
the intestinal mucosa.[2] LF promotes enterocytes proliferation
and diﬀerentiation.[3,4] Considering these important biological
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functions, LF has been incorporated in
many products as a dietary ingredient to
support the immune system.[1,5]
LF is a cationic glycoprotein from the
transferrin family.[6] It is present in the
secondary granules of neutrophils and in
exocrine secretions such as saliva, tears,
and milk.[7] In humans, LF is one of the
most abundant glycoproteins in breast
milk and is considered to play a role
in iron homeostasis and to have among
others antimicrobial, antiviral, and anti-
inﬂammatory properties.[8,9] LF is se-
creted in its open apo-form (iron-free
LF) and it binds to ferric ions (Fe3+)
to become the closed holo-form.[6] Hu-
man LF is more abundant in colostrum
(7 g L−1) and found at a lower con-
centration in mature breast milk (2–4
g L−1). For this reason, much attention
is given to its functional role in hu-
man health. Therefore, in the design
of infant formulas LF should closely
mimic the concentration and functional
aspects of LF in human breast milk.[2]
Human lactoferrin (hLF) and bovine lactoferrin (bLF) are not
identical.[10] They share a protein core with a similarity of 68–
70% but a pronounced diﬀerence occurs at their glycosylation
level. hLF and bLF diﬀer both in type of glycosylation, the num-
ber of potential N-glycosylation sites, and the glycan decoration
itself.[11] Glycosylation is a post-translational modiﬁcation of pro-
teins that aﬀects their structure, traﬃcking, recognition, and
biological functions.[12] It has been reported that glycosylation
in LF protects against proteolysis,[13] facilitates inter- or intra-
cellular signaling,[14] allows proper protein folding,[15] and mod-
ulates lectin N-glycan recognition processes.[16]
Bovine milk glycoproteins carry N- and O-linked glycans.
However, bLF carries only N-glycans with sugar moieties at-
tached via N-acetyl glucosamine to the asparagine residues of
the protein in the speciﬁc amino acid sequence Asn-X-Ser/Thr,
in which X can be any amino acid except proline.[17] hLF has
three potential sites for N-glycosylation, that is, Asn137, Asn478,
Asn623, that are always occupied, whereas bLF has ﬁve po-
tential sites, that is, Asn 281, Asn233, Asn368, Asn476, and
Asn545.[11,18] Four sites are always occupied, whereas Asn281
is glycosylated for approximately 30% in bovine colostrum, but
is reduced to 15% in mature milk.[19] N-glycans from hLF dif-
fer from bLF as they are highly branched, highly sialylated, and
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highly fucosylated complex-type structures and many contain
Lewis (x) epitopes.[20] Typically, the bLF complex-type N-glycans
include certain epitopes, not found in hLF N-glycans, that is,
Gal(α1-3)Gal(β1-4)GlcNAc (αGal), GalNAc(β1-4)GlcNAc (Lacd-
iNAc), and N-glycolylneuraminic acid (Neu5Gc).[21,22] In total,
bLF contains 76% neutral, 9% mono-sialylated, and 15% di-
sialylated glycan structures. From the sialic acid content, 8.5%
has been reported to correspond to Neu5Gc.[21] Bovine lactofer-
rin (bLF) glycans have been classiﬁed as 65% oligomannose type,
while 35% remaining correspond to complex and hybrid type.[23]
Glycosylation is a tightly regulated process, considered to be
programmed, temporal and sensitive to dietary regime.[24,25] Most
importantly, there is growing evidence that glycoproteins play
a critical role in immune recognition and that this property is
linked to the structural diversity in glycosylation. Both bLF and
hLF are known to modulate the immune system via Toll-like
receptors (TLRs).[26] However, how this modulation via TLRs
is aﬀected by glycosylation is not yet well understood. There-
fore, in the present study, we investigated the eﬀect of modiﬁed
bLF structures (desialylated, demannosylated) and the eﬀect of
N-glycans (desialylated and demannosylated) isolated from bLF
on the signaling of NF-κB (nuclear factor kappa–light-chain en-
hancer of activated B cells) via TLRs. Our study showed that these
variations in glycans decorations of bLF inﬂuence signaling of
TLR-3, TLR-4, and TLR-8.
2. Experimental Section
2.1. Preparation of Bovine Lactoferrin Modiﬁed Structures
bLF was isolated from pooled cow milk and was obtained from
Friesland Campina (Amersfoort, The Netherlands). This com-
pound was subjected to diﬀerent treatments to alter its native
structure. Samples of 500mg bLFwere incubatedwith either sial-
idase (Arthrobacter ureafaciens, Sigma-Aldrich Chemie B.V.) or α-
mannosidase (Canavalia ensiformis, Sigma-Aldrich Chemie B.V.).
Samples of bLF were dissolved at a concentration of5mgmL−1
in 50 mM sodium acetate (pH 5.0). The buﬀer for the mannosi-
dase assay was supplemented with 1mM of calcium and zinc. Ei-
ther sialidase (1 mUmg−1 protein) or mannosidase (5 mUmg−1
protein) was added and incubations were performed overnight
at 37 °C with continuous agitation. After 16 h, 1 mU mg−1 en-
zyme was added to the sialidase and incubated for 24 h. The in-
cubation at 37 °C does not denaturalize the protein or alter its
function. The heat-induced denaturalization of bLF occurs above
a temperature range of 70 °C and 90 °C and at pH lower than
5.0.[27–29]
The resulting products were dialyzed (SnakeSkin Dialysis Tub-
ing, 10 kDa MWCO, 22 mm, ThermoFisher Scientiﬁc, Waltham,
MA) against running ﬁltered water for 24 h to remove cleaved
monosaccharides and buﬀer salts. After lyophilisation, the dia-
lyzed bLF was subjected to a monosaccharide analysis to evalu-
ate the remaining sialic acid andmannose content. When the de-
sired modiﬁcations were complete (>90% of sialic acid removed
or a reduction of 25% of mannose), portions (50 mg) of the mod-
iﬁed proteins were stored for the experiments together with the
intact proteins.
Glycans were released from intact and modiﬁed bLF struc-
tures by incubation with PNGase F. Lyophilized bLF was
dissolved at a concentration of 2.5 mg mL−1 in 100 mM
sodium phosphate buﬀer (pH 7.5). SDS and β-mercapto ethanol
(Sigma-Aldrich Chemie B.V.) were added to a concentration
of 0.25% and 1%, respectively, and the protein denatured by
heating at 85 °C for 30 min. Denatured protein was alkylated by
addition of iodoacetamide to a concentration of 20 mM (55 °C;
30 min). Nonidet P-40 (NP-40, Sigma-Aldrich Chemie B.V.) was
added at a ﬁnal concentration of 1%. PNGaseF (Flavobacterium
meningosepticum, New England Biolabs, Ipswich, UK) was added
at a concentration of 50 U mg−1 of bLF protein and the solution
incubated overnight at 37 °C with continuous agitation. Com-
pletion of the PNGase F digestion was checked by SDS-PAGE.
The released glycans were isolated by a sequence of puriﬁcation
steps, including acetone precipitation, C18, and graphitized
carbon solid-phase extraction (Valk-Weeber et al., in press). Purity
of the obtained glycans was established by monosaccharide anal-
ysis and 1D 1H NMR spectroscopy (described in the Supporting
Information, Materials and Methods).
2.2. Cell Culture of Reporter Cell Lines
Reagents such as selection media, Quanti-Blue reagents, TLR
agonists, and THP1 (human acutemonocytic leukemia) and TLR
reporter cell lines were purchased from InvivoGen (Toulouse,
France). The THP1 reporter cell line express TLRs and contains
a construct for secreted embryonic alkaline phosphatase (SEAP)
coupled to the NF-κB/AP-1 promoter. This THP-1 cell line car-
ries extra inserts for the cosignaling molecules MD2 and CD14.
The second THP-1 cell line expresses a nonfunctional form of
the TLR adaptor MyD88 (myeloid diﬀerentiation primary re-
sponse protein 88). Additionally, nine human embryonic kidney
HEK293-Blue reporter cell lines (InvivoGen) containing indi-
vidual constructs for TLR-2, TLR-3, TLR-4, TLR-5, TLR7, TLR-8,
and TLR-9 were used.[30,31] All the cell lines carry a construct
for SEAP coupled to the NF-κB/AP-1 promoter. Both THP1 cell
lines were maintained in RPMI1640. The culture medium was
enriched with 10% heat-inactivated fetal bovine serum, sodium
bicarbonate NaHCO3 (1.5 g L−1), l-glutamine (2 mM Sigma-
Aldrich Chemie B.V), glucose (4.5 g L−1 Sigma-Aldrich Chemie
B.V), HEPES (10 mM Sigma-Aldrich Chemie B.V), sodium
pyruvate (1.0 mM Sigma-Aldrich Chemie B.V), penicillin–
streptomycin (50 U mL−1–50 μg mL−1, Sigma-Aldrich Chemie
B.V), and normocyn (100 μg mL−1, Sigma-Aldrich Chemie
B.V). The HEK-Blue cell lines were maintained in DMEM (Life
Technologies Europe B.V.) containing 10% heat inactivated fetal
bovine serum, l-glutamine (2.0 mM-Sigma-Aldrich Chemie
B.V), glucose (4.5 g L−1, Sigma-Aldrich Chemie B.V), penicillin-
streptomycin (50 U mL−1–50 μg mL−1 Sigma-Aldrich Chemie
B.V), and normocyn (100 μg mL−1 Sigma-Aldrich Chemie B.V).
HEK cells were grown to approximately 80% of conﬂuence. After
culturing for 3 passages, all reporter cell lines were maintained
on selection media according to the manufacturer’s protocol.
2.3. THP1 Reporter Cells Lines Stimulation
THP1 cells were centrifuged for 5 min at 300 g. The cell
density per well indicated by the manufacturer (Table 1)
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Table 1. Summary of the agonists, agonist concentrations, and cell density applied for the stimulation experiments
Cell line Cell density Agonist (positive control) Agonist concentration
(cell mL−1)
THP1MD2CD14 1 × 106 LPS-EK 10 μg mL−1
Lipopolysaccharides from Escherichia coli K12
THP1MyD88 def 2 × 106 Tri-DAP 100 μg mL−1
L-ala-γ -d-Glu-mDAP
HEK-hTLR2 2.8 × 105 FSL-1 1 μg mL−1
lipopeptide
HEK-hTLR3 2.8 × 105 Poly (I:C) LMW) 5 μg mL−1
polyinosinic–polycytidylic acid
Low molecular weight
HEK-hTLR4 1.4 × 105 LPS-EK 0.1 μg mL−1
Lipopolysaccharides from E. coli K12
HEK-hTLR5 1.4 × 105 Rec-FLA-ST 10 μg mL−1
Flagellin from Salmonella typhymurium
HEK-hTLR7 2.2 × 105 CL246 5 μg mL−1
Adenine analog
HEK-hTLR8 2.2 × 105 ssRNA40/LyoVec 50 μg mL−1
Singled-stranded RNA
HEK-hTLR9 4.5 × 105 ODN 2006 10 μM
Class B CpG oligonucleotide
was accomplished by appropriate dilution in culture medium.
Next, in a ﬂat bottom 96-well plate, 100 μL of this cell suspension
plus 10 μL of stimulus were added per well. The plate was incu-
bated for 24 h at 37 °C and 5% CO2. The stimulus consisted of
bLF proteins and its derivates at 2 mg mL−1, isolated bLF glycan
fractions and its derivates at 1.2 mg mL−1. The culture medium
and endotoxin free-water were used as negative controls. The ac-
tivity of SEAP converts the pinkQuanti-Blue substrate to blue. Af-
ter 24 h, the media supernatant was mixed with the Quanti-Blue
in a ratio of 1:10 and incubated for 1 h at 37 °C and 5% CO2. The
NF-kB release was quantiﬁed at 650 nm using a Benchmark Plus
Microplate Reader using Microplate Manager 5.2.1 version for
data acquisition. The assays were performed with three technical
repeats and each experiment was repeated three to ﬁve times.
2.4. TLR Activation and Inhibition Assay
HEK-Blue cell lines were detached from the bottom ﬂask after
which the cells were centrifuged and re-suspended according to
manufacturer’s protocol (Table 1). Later the cells were seeded at
diﬀerent cell densities (Table 1) in 96-well plates at 100 μL per
well. The cells were treated with 10μL of sample. The plates were
incubated for 24 h at 37 °C and 5% CO2. After this period, 20 μL
of supernatant weremixed with 180μL of Quanti-Blue in ﬂat bot-
tom 96-well plates. The plate was incubated for 1 h at 37 °C and
5% CO2. Activation was studied by comparing the NF-κB release
of nontreated cells with the NF-κB release from the treated cells.
Inhibition of TLRs was studied by comparing the NF-κB release
of TLRs agonist with the NF-κB release of cells treated with TLR
agonist and sample. After the incubation, the analysis of SEAP
was performed in the same fashion as described for the THP1
cell lines.
2.5. Statistical Analysis
Values were expressed as median with interquartile range. Nor-
mal distribution of the data sets was excluded using the Shapiro–
Wilk and Kolmogorov–Smirnov tests. Statistical comparisons
were performed usingMann–Whitney nonparametricU tests for
unpaired observations and (two-tailed). A p-value< 0.05 was con-
sidered statistically signiﬁcant. p values < 0.05 are denoted with
*, p values < 0.01 are denoted with ** and p values < 0.001 are
denoted with ***.
3. Results
3.1. Bovine Lactoferrin Induces Myd88-Dependent Activation of
THP1 MD2 CD14 Cells
To determine whether bLF has immune stimulating eﬀects, we
stimulated the THP1MD2CD14 cell linewith bLF at a concentra-
tion of 2 mg mL−1 for 24 h. As shown in Figure 1, bLF enhanced
the release of NF-κB from 0.0044 to 0.86 (p < 0.01).
To study whether the MyD88 protein adaptor mediates this ac-
tivation, we also performed this study with THP1 MD2 CD14
with a truncated MyD88.[27,28] An activation of NF-κB in THP1
MD2 CD14 but not in THP1 with a truncated Myd88 when incu-
bated with bLF conﬁrms that the activation was Myd88 and TLR
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Figure 1. bLF stimulates THP1 MD2 CD14 via TLRs. The cell lines THP1 MD2 CD14 and THP1 MD2 CD14 with a truncated MyD88 adaptor were
stimulated with 2 mg mL−1 of bLF after which NF-κB activation was measured by spectrophotometry at 650 nm. The release of NF-κB after bLF
incubation was compared with the release of NF-κB of nontreated cells. NF-κB release is expressed in arbitrary units. Data are represented as median
with interquartile range (n = 5). Statistical diﬀerences were measured using Mann–Whitney test (**p < 0.01, ***p < 0.001).
Figure 2. The absence of sialic acid has an eﬀect on the release of NF-κB. THP1 MD2 CD14 cells were stimulated with 2 mg mL−1 of bLF without
sialic acid (A) and bLF with 25% reduced mannose on the N-glycan chains(B). NF-κB activation was measured by spectrophotometry at 650 nm. NF-κB
release is expressed in arbitrary units. Data are represented as median with interquartile range (n = 5). Statistical diﬀerences were measured using
Mann–Whitney test (**p < 0.01).
dependent (Figure S1). TRIDAP is a suitable control because it
signals via NOD-1 receptors.
3.2. Consequences of Structural Modiﬁcations on bLF N-Glycans
In order to gain insight into the eﬀects of diﬀerent glycosyla-
tion patterns in the activation of PRRs, a series of modiﬁed bLF
fractions were prepared and tested on the THP1 MD2 CD14
cell lines. The iron saturation of bLF ranges from 15 to 19%.[8]
Therefore, under the dialysis conditions (pH 5.0), the bLF is ex-
pected to shift from the iron-bound holo-form to apo-form with
approximately 4–8% of iron because iron is retained in the dialy-
sis membrane.[29,32] In order to completely remove the iron form
the bLF, a pH below 2 is required but this was avoided as it might
compromise function of the glycoprotein.[32,33] This dialysis step
was associated with a reduction in THP1 cell activating capacity
(Figure S2), possibly due to this change in form.
As shown in Figure 2A, desialylated bLF induced a statistical
signiﬁcantly lower activation of THP1 MD2 CD14 cells (p <
0.01). The reduction in the mannose content had the opposite
eﬀect. It enhanced the response of THP1 MD2 CD14 cell almost
twofold when compared with bLF itself (Figure 2B)
Finally, to get further insight into structure–function relation-
ships, also the eﬀects of the isolated N-glycan groups were tested.
Fractions of the intact, desialylated, and the demannosylated bLF
were treated with PGNase F to release the N-glycans from the
protein. The incubation on THP1MD2 CD14 cells with intact N-
glycans and desialylated and demannosylated N-glycans showed
no activation (Figure S3).
3.3. Bovine Lactoferrin Eﬀects on TLRs
The results from the THP1 cell stimulation showed that TLRs
are engaged in NF-κB signaling by bLF proteins. Next, we investi-
gated which TLRs were involved and whether or not the intact, di-
alyzed, desialylated or demannosylated bLFs inﬂuence the signal-
ing via speciﬁc TLR receptors. To this end, HEK cells expressing
TLR-2, TLR-3, TLR-4, TLR-5, TLR-7, and TLR-9 were incubated
with the diﬀerent types of (un)modiﬁed bLF. HEK cells express-
ing TLR-2, TLR-5, TLR-7, TLR-9 were not signiﬁcantly activated
or inhibited by intact bLF or its counterparts with N-glycan mod-
iﬁcations (Figures S4, S5, S6, and S7, respectively). Additionally,
when these cell lines were treated with the isolated intact, desialy-
lated, and demannosylated N-glycans, no eﬀects were observed.
This was diﬀerent for TLR-3, TLR-4, and TLR-8.
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Figure 3. Inhibitory eﬀects of bLF proteins on HEK- TLR-3 cells. The cells
were coincubated with the bLF structures and with the speciﬁc agonist for
TLR-3 Poly(I:C) LMW (5 μg mL−1). NF-κB release was measured by spec-
trophotometry at 650 nm. Median and interquartile range of activation is
plotted as NF-κB release (n = 3). Statistical diﬀerences were calculated
with Mann–Whitney test (**p < 0.01).
3.4. TLR-3 Inhibition of NF-κB Release by Modiﬁed bLF Proteins
bLF did have an inhibitory rather than an activating eﬀect onTLR-
3 cells.WhenHEK cells carrying TLR-3were incubatedwith poly-
IC LMW combined with bLF, we observed almost a complete
blockage of the signaling via TLR-3. This was not dependent on
the sialic acid or mannose decoration on the N-glycans attached
to the bLF: the desialylated and demannosylated forms exhibited
similar, if not identical inhibitory eﬀects on TLR-3 (p < 0.01).
The NF-κB released from the bLF was 10.03-fold (p < 0.01)
lower when compared to the NF-κB released from the positive
control. The desialylated bLF showed 8.05-fold (p < 0.01) and the
demannosylated bLFs 11.64-fold (p < 0.01) lower response when
compared to the Poly (I:C) activation (Figure 3).
When the isolated bLF N-glycans were incubated with this cell
line, neither activation nor inhibition was observed (Figure S3).
This suggest that the presence of the protein core is necessary to
result in the inhibition of Poly (I:C) induced TLR-3 activation.
3.5. Bovine Lactoferrin Proteins Induce Strong Activation of
TLR-4
As shown in Figure 4, bLF and its desialylated and deman-
nosylated counterparts activated TLR-4. The HEK-Blue TLR-4
cells were also treated with the isolated N-glycans, but these
compounds did not exert activation. This may suggest that the
protein core of bLF and not the isolated N-glycans play a role
in the activation of TLR-4. To exclude that the observed TLR-4
Figure 4. bLF glycosylation pattern inﬂuence in the release of NF-κB in
HEK-Blue TLR-4. Cells were incubated with bLF proteins at 2mgmL−1 and
isolated N-glycans and desialylated and demannosylated N-glycans at 1.2
mgmL−1. Culturemedium served as negative control. NF-κB release is ex-
pressed in arbitrary units. NF-κB activation was measured by spectropho-
tometry at 650 nm. Data are represented as median with interquartile
range (n= 5). Statistical diﬀerences were measured using Mann–Whitney
test (***p < 0.001).
activation was mediated or interfered by LPS contamination, the
samples were treated with Polymyxin B.
As shown in Figure 5A, Polymyxin B does not induce the
release of NF-κB in TLR-4. When LPS was coincubated with
Polymyxin B, a complete blockade of LPS signaling was ob-
served. In Figure 5B, the neutralized bLF showed 1.67-fold (p
< 0.001) increased NF-κB activation compared with the control
(nontreated cells). Similar to bLF, neutralized desialylated and
demannosylated bLF increased 1.38-fold (p < 0.01) and 2.85-fold
(p < 0.001), respectively, the release of NF-κB (Figure 5C and D).
Furthermore, with the exclusion of LPS contamination, the
eﬀects of the glycosylation proﬁles of bLF were more evident.
As shown in Figure 6, the desialylated bLF activation (0.0930, p
< 0.001) was lower when compared with the activation by bLF
(0.058, p < 0.001). In contrast, the demannosylated bLF activa-
tion (0.1918, p < 0.001) was higher compared with the activation
exerted by bLF. The desialylated bLF showed 2.06-fold (p< 0.001)
lower NF-κB activation compared with the demannosylated bLF.
3.6. TLR-8 Inhibition of NF-κB Release by Modiﬁed bLF Isolated
N-Glycans
TLR8 was neither activated nor inhibited by bLF (Figure S8).
However, it was inhibited by the N-glycans isolated from bLF.
This was studied with the TLR agonist ssRNA40. As shown in
Figure 7, the N-glycans isolated from bLF reduced the NF-κB
release 2.12-fold (p < 0.05). Comparable inhibitory eﬀects
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Figure 5. bLF proteins structural inﬂuence in the release of NF-κB in HEK-Blue TLR-4. The eﬀect of Polymyxin B blockade at 100μg mL−1 was conﬁrmed
by coincubation of this cationic compound with LPS at 10 μg mL−1 (A). LPS neutralization was also achieved when Polymixyn B was coincubated with
bLF (B), the desialylated bLF (C), and demannosylated bLF (D) at a concentration of 2 mg mL−1. Culture medium served as negative control. NF-κB
activation was measured by spectrophotometry at 650 nm. The statistical diﬀerences were measured with unpaired t-test with (n = 4) (**p < 0.01, ***p
< 0.001).
were observed with the desialylated (2.47-fold, p < 0.05) and
demannosylated bLF (2.45-fold, p < 0.05) counterparts.
4. Discussion
The role of bLF in regulation of the innate immune system is
of considerable interest for its nutraceutical and pharmacologi-
cal potential as dietary supplement or treatment adjuvant. The
immunomodulatory properties of bLF have been previously de-
scribed in vitro[34–37] and in vivo.[38,39] However, the role of glyco-
sylation patterns on its biological activity is not well understood.
To the best of our knowledge, in the present study, we show for
the ﬁrst time that sialylation and mannosylation of bLF alter the
immunomodulatory properties by profound diﬀerences in sig-
naling of NF-κB mediated via TLRs.
The innate function is guarded by pattern recognition recep-
tors (PRRs) and involved in the regulation of host–commensal
interactions.[40] The most studied PRRs are TLRs that are local-
ized in the cell surface or within endosomes and can be expressed
by intestinal epithelial cells, macrophages, dendritic cells, B cells,
T cells, and stromal cells.[41] To determine whether bLF and its
desialylated and demannosylated forms could be sensed by TLRs
or other PRRs, we used the THP1 cell line, which is equipped
with most of the known PRRs.[42] Combined with a THP1 cell
line with a truncated MyD88 adaptor, which is necessary for the
signaling via TLR, the data showed that the activation of bLF and
its modiﬁed counterparts was mainly TLR dependent.
Sialylation of LF is essential for TLR signaling as the desia-
lylated form of bLF was signiﬁcantly lower compared to its sialy-
lated counterpart. The absence or presence of sialic acid has been
found to be both unfavorable and favorable for bLF structure sta-
bility and its biological activity.[43] On one hand, the lack of sialic
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Figure 6. bLF proteins glycosylation proﬁle inﬂuences the release of NF-
κB in HEK-Blue TLR-4. Cells were incubated with bLF proteins at 2 mg
mL−1 and Polymyxin B at 100 μg mL−1. The statistical diﬀerences were
measured with unpaired t-test (n = 4) (*p < 0.05, **p < 0.01, ***p <
0.001).
acid on bLF has been shown to reduce its ability to bind to iron
up to as much as 90%.[44] The iron-binding capacity of LF is in-
volved in the maintenance of iron homeostasis.[23] On the other
hand, the anti-rotavirus activity of bLF has been observed to in-
crease upon the removal of the sialic acid.[45] De-sialylation of LF
has been assumed to favor the opening of other functional epi-
topes on LF that increase the interaction between the rotavirus
and bLF.[45] These ﬁndings are in line with studies on epitopes
recognized by rotavirus V8.[46] However, our data suggest that sia-
lylation can also contribute to immune responses and thereby
also contributes to the clearance of pathogens.
In contrast, the reduced mannose bLF structure has an oppos-
ing eﬀect on immunomodulation since it had a signiﬁcant higher
signaling compared with the intact bLF. The type of oligoman-
nose structures on bLF have been described to be diverse, but its
eﬀects on themodulation of the innate response are unknown.[21]
The antibacterial activity of bLF is partially attributed to its oligo-
mannose type glycans that act as decoy receptors that prevent bac-
terial adhesion.[12] Oligomannose glycans have a high aﬃnity for
Escherichia coli type 1 ﬁmbrial lectin, thus facilitating adhesion
of bacteria to bLF instead of the intestinal mucosa.[47] bLF has
shown to be more eﬀective inhibitor than hLF of DC-SIGN, a C-
type lectin that mediates the internalization of HIV-1 virus. This
occur as a consequence of the binding of the oligomannose gly-
cans of bLF to the DC-SIGN.[48] This combined with enhanced
TLR signaling as shown here might be mechanisms by which
mannose glycans contribute to prevention of disease.
Figure 7. Inhibitory eﬀects of isolated bLF N-glycans on HEK-TLR-8 cells.
The cells were coincubated with the bLF structures and with the speciﬁc
agonist for TLR-8 ssRNA40 (50 μg mL−1). NF-κB was measured by spec-
trophotometry at 650 nm. Median and interquartile range of activation is
plotted as NF-κB release (n = 5). Statistical diﬀerences were calculated
with Mann–Whitney test (*p < 0.05).
To the best of our knowledge, inhibitory eﬀects of TLR-3 by
bLF have not been reported before. Nevertheless, it has been re-
ported that the expression of TLR-3 in mice small intestines can
be downregulated by the oral administration of LF.[49] TLR-3 me-
diates immune responses against viral infections upon activation
by its ligand double-stranded RNA.[50] However, little is known
about how this receptor is regulated or how its signaling is ini-
tiated in response to its agonists.[51] The in vivo injection of Poly
(I:C), a ligand of TLR-3, results in the activation of dendritic cells
and natural killer cells. Uncontrolled or sustained responses via
TLR-3 have been associated with increased mortality and mor-
bidity in infections such as Nile disease, Phlebovirus, vaccinia,
and inﬂuenza A.[52] A downregulation of TLR-3 pathways by LF
is a potential target for the therapeutic treatment of such diseases
and can possibly be manipulated by changing the glycosylation
of LF.
bLF activated TLR-4. bLF contains a basic region close to
the N-terminus capable to bind to anionic molecules such as
lipid A from LPS.[36,53] This characteristic confers LF its anti-
endotoxic eﬀect. The work of Yong et al. suggests that LPS is even
necessary for TLR-4 signaling and even part of the immunomod-
ulatory function[35] and anti-microbial activity of LF.[34,54,55] To
conﬁrm that the bLF and its desialylated and demannosylated
counterparts and not contaminating LPS induced release of NF-
κB, the LPS content was neutralized with Polymyxin B. Once
the signaling of LPS was blocked, it was observed that the
signaling of the desialylated bLF was lower compared to the
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demannosylated form. The change in glycosylation proﬁle seems
to aﬀect the intensity of the signaling but not the signaling per
se. These results can occur as a consequence of TLR-4 coopera-
tion with glycan receptors. TLR-4 has been described to be regu-
lated by glycan receptors such as siglecs or C-type lectins. Siglecs
are receptors recognizing speciﬁcally structures decorated with
sialic acid. In particular, siglecs have been shown to act by slowing
down the activation of TLRs such as TLR-4.[56] In contrast, TLR-4
interacts with Dectin-1 and mannose receptors upon fungal in-
fection to induce lymphocyte proliferation.[57] Although TLR-4 is
key for the antibacterial activity of bLF, our study conﬁrms that
the signaling via TLR-4 is modulated by the composition of the
glycan chains.
Finally, unlike TLR-3 and TLR-4, the isolated glycans from
bLF and its desialylated and demannosylated forms inhibited
TLR-8. This type of interaction between carbohydrates and
TLR-8 is quite atypical because of the type of structures that
endosomal receptors recognize and its localization in endoso-
mal compartments.[58] TLR-8 senses ssRNA rich in adenylate-
uridylate present in viruses, small interfering RNAs, and im-
idazoquinoline compounds.[59] TLR-8 mediates the recognition
of self-RNA released from apoptotic cells.[60] The inappropriate
recognition of endogenous agonist like ssRNA through endoso-
mal TLRs contribute signiﬁcantly to autoimmune diseases.[61] It
has been described that circulating DNA or RNA complexes in
patients with systemic lupus erythematosus can induce cytokine
production and disease development. Therefore, the inhibition of
endosomic TLRs by isolated glycans has a therapeutic potential
for the treatment of autoimmune diseases.[62]
Our data demonstrate a pertinent role for sialylation and man-
nosylation of bLF in its immunomodulatory properties. We iden-
tiﬁed the PRRs TLR-3, TLR-4, and TLR-8 as principle target for
the N-glycans of bLF. As these receptors are involved in many
pathologies, our data do not only contribute to a better under-
standing of how bLF can have immunomodulatory properties.[6]
It also open new venues to manage disease with adapted bLF for-
mulations.
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